

Office of Sponsored Programs (OSP) Roundtable

New NIH Human Subjects Requirements

Guilaine Senecal, Assistant Director, Office of Research Integrity and Assurance Jamie Sprague, Sr. Grant & Contract Officer/Federal Team Lead, Office of Sponsored Programs





Agenda

- Updated definition of Clinical Trial
- Single Institutional Review Board (sIRB) requirements
- Certificate of Confidentiality (CoC)
- Forms E PHS Human Subjects and Clinical Trials Information Form



OSP Roundtable – New NIH Human Subjects Requirements Updated Definition of Clinical Trial



What has changed?

• NIH's definition of clinical trial has been updated to communicate a much broader applicability:

"A research study in which one or more **human subjects** are **prospectively assigned** to one or more **interventions** (which may include placebo or other control) to evaluate the effects of those interventions on **health-related biomedical or behavioral outcomes**."

NIH Policy Notice NOT-OD-15-015 (October 23, 2014) https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-015.html






Breaking down the definition

- **Prospectively assigned:** a pre-defined process (e.g., randomization) by which research participants are assigned to one or more arms (e.g., intervention, placebo, or other control) of a study
- Intervention: a manipulation of the research participant or their environment (e.g., use of a wearable device such as a Fitbit; diet or exercise; surgical technique)
- Health-related Biomedical or Behavioral Outcome: a pre-specified goal or condition that reflects the effect of the intervention(s) on participants' biomedical or behavioral status or quality of life (e.g., improvement of lung capacity; changes to psychological wellbeing)

Cornell University



Decision Tree for NIH Clinical Trial Definition



https://grants.nih.gov/policy/clinical-trials/CT-decision-tree.pdf



Example 1

A study involves the recruitment of school children to evaluate two different tools for monitoring food intake. Food consumption behavior will be measured by asking children to activate a pocket camera during meals and to use a diary to record consumed food. Changes to eating behavior will be assessed.

- **Does the study involve human participants?** Yes, children are human participants.
- Are the participants prospectively assigned to an intervention? Yes, the participants are prospectively assigned to two food monitoring methods.
- Is the study designed to evaluate the effect of the intervention on the participants? Yes, the study is designed to determine whether using the monitoring methods changes eating behavior.
- Is the effect being evaluated a health-related biomedical or behavioral outcome? Yes, eating behavior is a health-related outcome.

This study is a clinical trial.



Example 2

A study involves the recruitment of children at two schools to monitor eating behavior. Children's food choices will be monitored using a remote food photography method. Food consumption and the accuracy of food monitoring methods will be assessed.

- **Does the study involve human participants?** Yes, the children participating in this study are human participants.
- Are the participants prospectively assigned to an intervention? No, not in this context. The study involves observing and measuring eating behavior, but not modifying it. This is an observational study.

This study is not a clinical trial.



What are the implications of this change?

- With this broader definition, many more studies are classified as clinical trials and are therefore subject to additional human subjects compliance requirements, including;
 - All researchers on the protocol for the NIH-funded clinical trial study must complete training in Good Clinical Practice (GCP).
 - The study must be registered within 21 days of enrollment of first participant on ClinicalTrials.gov and must provide summary results and updates about the study as required.
 - For clinical trials funded by <u>any</u> federal agency, all consent forms must be posted online (website TBD) after the study is closed to recruitment and within 60 days of the end of data collection.



What are the implications of this change?

 Researchers and administrators will need to determine whether the project meets the definition of a clinical trial *prior to submitting a proposal to NIH for funding consideration*. Effective for due dates on or after January 25, 2018, NIH will require all applications involving one or more clinical trials be submitted through a Funding Opportunity Announcement (FOA) specifically designated for clinical trials.

Due Dates on or after
January 25, 2018All clinical trial applications MUST be submitted to an FOA
that allows clinical trials

 NIH is revising and reissuing all Parent Funding Opportunity Announcements (FOAs) to specify whether or not a proposal involving a clinical trial study will be accepted. See NIH Policy Notice NOT-OD-18-106 <u>https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-106.html</u>.



Next Steps: Cornell Researchers

• All researchers;

- Prior to starting your NIH proposal, determine whether your project is a clinical trial. Ask the Cornell IRB Staff at <u>irbhp@cornell.edu</u> for help if you are not sure!
- Work with your pre-award administrator and OSP Grant & Contract Officer to apply to the correct NIH Funding Opportunity Announcement (FOA).
- Add a few days to your proposal planning and preparation timeline.
- Clinical Trial researchers;
 - Have all study team members take Good Clinical Practices (GCP) training <u>http://www.oria.cornell.edu/training/citi/login/index.cfm</u>
 - Familiarize yourself with Clinicaltrials.gov and set up an account <u>https://grants.nih.gov/policy/clinical-trials/reporting/steps.htm</u>



Next Steps: Research Administrators

- Become familiar with;
 - The updated definition and determination criteria for clinical trials
 - Clinicaltrials.gov and the reporting requirements
 - Updated NIH Funding Opportunity Announcements (NOT-OD-18-106)
 - Forms E, especially the new PHS Human Subjects and Clinical Trials Information Form
- Work with all NIH researchers to;
 - Determine whether their project is a clinical trial. Ask the Cornell IRB Staff at <u>irbhp@cornell.edu</u> for help if you are not sure!
 - Ensure all proposals, both those that are and are not clinical trials, are submitted to the correct NIH Funding Opportunity Announcement (FOA)
- Add a few days to your proposal planning and preparation timeline.



NIH Resources

• Guidance

NIH's Definition of a Clinical Trial Website https://grants.nih.gov/policy/clinical-trials/definition.htm

NIH's Clinical Trial Case Studies Website https://grants.nih.gov/policy/clinical-trials/case-studies.htm

NIH's Good Clinical Practice (GCP) Training Website https://grants.nih.gov/policy/clinical-trials/good-clinical-training.htm

• Policy

NIH Policy Notice NOT-OD-15-015: Notice of Revised NIH Definition of "Clinical Trial" https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-015.html

NIH Policy Notice NOT-OD-17-118: NIH Announces New Review Criteria for Research Project Applications Involving Clinical Trials https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-118.html

NIH Policy Notice NOT-OD-18-106: Policy on Funding Opportunity Announcements (FOA) for Clinical Trials Takes Effect 1/25/2018 https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-106.html

NIH's Clinical Trials FAQs https://grants.nih.gov/grants/policy/faq_clinical_trial_definition.htm



OSP Roundtable – New NIH Human Subjects Requirements Single Institutional Review Board (sIRB) Requirements



What is a single Institutional Review Board (sIRB)?

- One IRB that is responsible for conducting an ethical review of, and coordinating, all human participant research performed at all the locations in a multi-site study.
- Role of the sIRB:
 - Conducts ethical review for studies at all sites, including recruitment, applications, consent forms, incident reports, data and privacy, in keeping with Common Rule requirements.
 - May also serve as Privacy Board (HIPAA Privacy Rule use/disclosure of PHI for research).
 - Handles all changes to the study and ensure that they are uniformly implemented, ensure all concerns are addressed, maintain documentation, correspond with the NIH and regulators.
- Role of participating sites:
 - Rely on sIRB to carry out review functions and report to sIRB (unanticipated problems, study progress, information regarding local context issues), meet all IRB requirements for study at their site (local review, documentation, training, oversight, incident reporting, etc.)



What has changed?

• NIH has a new policy, intended to streamline the IRB review process, harmonize IRB requirements for an NIH-funded study, and reduce administrative burden.

All multi-site projects with non-exempt human participant research (clinical and nonclinical) where the same research protocol is conducted at more than one domestic site will be required to use a single Institutional Review Board (sIRB).

- Applies to all competing grant applications (new, renewal, revision, resubmissions) due on or after January 25, 2018, and all contract solicitations published starting January 25, 2018.
- Does not apply to international sites, or to Career Development (K), Research Training (T), or Fellowship (F) mechanisms.



What are the implications of this change?

- If the NIH proposal involves conducting the same research at multiple locations, the proposal *must* include an <u>sIRB Plan</u>
 - Plan must indicate the sIRB, confirm that participating sites will adhere to the sIRB Policy, describe communications between sites and sIRB
 - sIRB costs might be permitted as direct charges (Talk to you GCO!)
 - If awarded, all participating sites must execute an Authorization Agreement & the sIRB
 Plan will be incorporated into the Notice of Award (NOA) as a term and condition

The administrative responsibility of the Single IRB is very significant. Do not assume Cornell can act as sIRB. Contact Cornell IRB (<u>irbhp@cornell.edu</u>) well in advance of proposal submission.



NIH Resources

• Guidance

NIH's Single IRB policy for Multi-site Research Website https://grants.nih.gov/policy/clinical-trials/single-irb-policy-multi-site-research.htm

• Policy

NIH Policy Notice NOT-OD-16-094: Final NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-094.html

NIH Policy Notice NOT-OD-18-003: Guidance on Exceptions to the NIH Single IRB Policy https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-003.html

NIH Policy Notice NOT-OD-18-004: Guidance on Implementation of the NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-004.html



OSP Roundtable – New NIH Human Subjects Requirements Certificates of Confidentiality



What is a Certificate of Confidentiality?

• A Certificate of Confidentiality (CoC) protects the privacy of research participants by prohibiting disclosure of participants' identifiable, sensitive information in response to legal demands, such as a subpoena.



What has changed?

- Effective October 1, 2017, for NIH-funded research active on December 13, 2016;
 - All research that collects or uses identifiable, sensitive information is deemed to be issued a CoC
 - No documentation will be given determination of whether a CoC applies is left to the institution and researchers
 - Previously, obtaining CoC protections required an application to NIH-- not all requests were granted
- For non-NIH studies, PIs may request a CoC (the new, automatic issuance only applies to NIH studies) if they believe it is necessary to protect participants



What are the implications of this change?

- If a CoC applies to an NIH-funded study:
 - The IRB office will inform the PI during the approval process
 - The researcher may not disclose protected information to any person not connected with the research, including for legal proceedings
 - The consent should inform participants about the CoC
 - Collaborators & other recipients of identifiable information or biospecimens are subject to the same restrictions, and the PI is responsible for communicating this to collaborators



NIH Resources

• Guidance

NIH's Certificates of Confidentiality Website https://humansubjects.nih.gov/coc/index

• Policy

NIH Policy Notice NOT-OD-17-109: Notice of Changes to NIH Policy for Issuing Certificates of Confidentiality https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html



OSP Roundtable – New NIH Human Subjects Requirements Forms E - PHS Human Subjects and Clinical Trials Information



SF 424 (R&R) Forms Version E

• Effective for due dates on or after January 25, 2018, the Forms E Application package, including the new Human subjects and Clinical Trials Information form, is required for all applications submitted to NIH.

Application Form Instruction			
Application Instructions	Description	SF424 (R&R) - Version D Use for due dates on and before January 24, 2018	SF424 (R&R) - Version E Use for due dates on and after January 25, 2018
G General Instructions	Comprehensive guidance for research, training, fellowship, career development, multi-project, and small business applications	HTML / PDF	HTML / PDF

https://grants.nih.gov/grants/how-to-apply-application-guide.html



PHS Human Subjects and Clinical Trials Information Form

- New form making it's debut in Forms E!
- Purpose:
 - Consolidates human subjects, inclusion enrollment, and clinical trial information previously collected across multiple agency forms
 - Incorporates structured data fields
 - Collects information at the study-level
- PHS 398 Research Plan has also been updated to remove the human subjects attachments Protection of Human Subjects, Data Safety Monitoring Plan, Inclusion of Women and Minorities, and Inclusion of Children.

PHS Human Subjects and Clinical Trials Information		(Check Form for Errors Save			
View Burden Statement	OMB Number: 0925-0001 Expiration Date: 03/31/2020	Study Record: PH	S Human Subjects and Clinica	I Trials Information		
Please complete the human subjects section of the Research & Related Other Project Information form prior to completing this form.		* Always required field		OMB Number: 0925-0001 Expiration Date: 03/31/2020		
The following items are taken from the Research & Related Other Project Information form and displayed here for your reference. Any char fields must be made on the Research & Related Other Project Information form and may impact the data items you are required to complete	nges to these	Section 1 - Basic Information				
Are Human Subjects Involved?	-	1.1. * Study Title (each study title must be uniqu	e)			
Is the Project Exempt from Federal regulations?			.,			
Exemption number: 1 2 3 4 5 6 7 8		1.2. * Is this Study Exempt from Federal Regulat	ions? Yes No			
If No to Human Subjects		4.2. Examplies Number	1 2 3 4 5 6	7 🗆 8		
Does the proposed research involve human specimens and/or data? Yes No		1.4. * Clinical Trial Questionnaire If the answers to all four questions below are yet				
		1.4.a. Does the study involve human participants? Yes No 1.4.b. Are the participants prospectively assigned to an intervention? Yes No				
Add Attachment Delete Attachment View Attachment			effect of the intervention on the participants			
Skip the rest of the PHS Human Subjects and Clinical Trials Information Form.		1.4.d. is the effect that will be evaluated a h	ealth-related biomedical or behavioral outco	me? Yes No		
If Yes to Human Subjects		1.5. Provide the Clinical Trials.gov Identifier (e.g.	NCT8/654321) for this trial, if applicable			
Add a record for each proposed Human Subject Study by selecting 'Add New Study' or 'Add New Delayed Onset Study' as appropria studies are those for which there is no well-defined plan for human subject involvement at the time of submission, per agency policie						
Studies are mose to which there is no were enned plan to noman subject involvement at the time of submission, per agency power Studies. For delayed onset studies, you will provide the study name and a justification for omission of human subjects study informat	tion	Section 2 - Study Population Characteristics				
Other Requested Information	-					
Add Attachment Delete Attachment View Attachment	2.1. Conditions or Focus of Study					
	_	X Add Marco Dana dition				
Click here to extract the Human Subject Study Record Attachment	l	Add New Condition				
Study Record(s)		2.2. Eligibility Criteria				
Attach human subject study records using unique filenames.						
	e Attachment View Attachment	2.3. Age Limits Minimum Age	▼ Maxim	um Age		
Add New Study		2.4. Inclusion of Women, Minorities, and Childre	n	Add Attachment Delete Attachment View Attachment		
Delayed Onset Study(ies)		2.5. Recruitment and Retention Plan		Add Attachment Delete Attachment View Attachment		
Anticipated Study Title Clinical Justifica Trial?	ation	2.6. Recruitment Status		×		
X		2.7. Study Timeline		Add Attachment Delete Attachment View Attachment		
Add Attachment Delete Atta	achment View Attachment	2.8. Enrollment of First Subject				
Add New Delayed Onset Study		Inclusion Enrollment Report(s)				

Add Inclusion Enrollment Report

Inclusion Enrollment Report

. * Using an Existing Dataset or Resource	Yes No	
2. * Enrollment Location Type	Domestic Foreign	
3. Enrollment Country(ies)		
×		•
Add New Country		
. Enrollment Location(s)		
5. Comments		

Planned

	Ethnic Categories								
Racial Categories	Not Hispar	iic or Latino	Hispanic	Total					
	Female	Male	Female	Male					
American Indian/ Alaska Native	0	0	0	0)				
Asian	0	0	0	0)				
Native Hawaiian or Other Pacific Islander	0	0	0	0)				
Black or African American	0	0	0	0)				
White	0	0	0	0)				
More than One Race	O	0	O	0)				
Total	0	0	0	0)				

Cumulative (Actual)

Remove Inclu

0 0 0

	Ethnic Categories									
	Not Hispanic or		atino Hispanic or Latino			no	Unknown/Not Reported Ethnicity			Total
Racial Categories	Female	Male	Unknown/ Not Reported	Female	Male	Unknown/ Not Reported	Female	Male	Unknown/ Not Reported	
American Indian/ Alaska Native	a	0	0	0	0	0	0	0	ū	0
Asian	0	0	0	0	0	0	0	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0	0	0	0	0
Black or African American	Q	0	0	D	0	0	0	0	Q	0
White	0	0	0	0	0	0	0	0	0	0
More than One Race	a	0	0	0	D	0	O	0	a	D
Unknown or Not Reported	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	Q	0	0	0	0	0	0
< Previous Report				F	Report 1 of 1					Next Report >
<< First Report				D	elete Report				L	ast Report >>

	Section 3 - Protection and Monitoring Plans	4.2.g. Allocation					
	3.1. Protection of Human Subjects Delete Attachment View Attachment						
ſ	3.2. Is this a multi-site study that will use the same protocol to conduct non-exempt human subjects research at more than one domestic site? Yes No N/A If yes, describe the single IRB plan Add Attachment Delete Attachment	4.3. Outcome Measures X Name Type Time Frame					
	3.3. Data and Safety Monitoring Plan Add Attachment Delete Attachment View Attachment	Brief Description					
7	3.4. Will a Data and Safety Monitoring Board be appointed for this study?	Add New Outcome					
	Yes No	4.4. Statistical Design and Power Add Attachment User Attachment View Attachment					
	3.5. Overall Structure of the Study Team Add Attachment User Attachment View Attachment	4.5. Subject Participation Duration					
	Section 4 - Protocol Synopsis	4.6. Will the study use an FDA-regulated intervention?					
	4.1. Brief Summary	4.6.a. If yes, describe the availability of investigational Product (IP) and Investigational New Drug (IND)/Investigational Device Exemption (IDE) status					
		Add Attachment Delete Attachment View Attachment					
	4.2. Study Design	4.7. Dissemination Plan					
	4.2.a. Narrative Study Description						
		Section 5 - Other Clinical Trial-related Attachments					
	4.2.b. Primary Purpose	5.1. Other Clinical Trial-related Attachments Add Attachments Delete Attachments View Attachments					
	4.2.c. Interventions						
	x Intervention Type						
	Name						
	Description						
	Add New Intervention						
	4.2.d. Study Phase						
	Is this an NIH-defined Phase III clinical trial? 📃 Yes 📃 No						
	4.2.e. Intervention Model						
	4.2.1. Masking Yes No Participant Care Provider Investigator Outcomes Assessor						



NIH Resources

• Guidance

PHS Human Subjects and Clinical Trials Information Form Walk-through https://www.youtube.com/watch?v=nz9NWFhYOG8

New Human Subjects and Clinical Trial Information Form Website https://grants.nih.gov/policy/clinical-trials/new-human-subject-clinical-trial-info-form.htm

Annotated Forms Version E For NIH Grant Applications due on/after January 25, 2018 https://grants.nih.gov/grants/ElectronicReceipt/files/Annotated_Forms_General_FORMS-E.pdf

Policy

SF 424 (R&R) Forms Version E – Significant Changes https://grants.nih.gov/grants/how-to-apply-application-guide/forms-e/general/g.120-significant-changes.htm

SF 424 (R&R) Forms Version E – PHS Human Subjects and Clinical Trials Information Guidelines https://grants.nih.gov/grants/how-to-apply-application-guide/forms-e/general/g.500-phs-human-subjects-and-clinical-trials-information.htm



Overview of New NIH Policies on Human Subjects Research



https://grants.nih.gov/policy/clinical-trials/tutorial/story_html5.html?lms=1



OSP Roundtable – New NIH Human Subjects Requirements Questions?



OSP Roundtable – New NIH Human Subjects Requirements

Guilaine Senecal

Assistant Director Office of Research Integrity and Assurance gds64@cornell.edu

Jamie Sprague Sr. Grant & Contract Officer/Federal Team Lead Office of Sponsored Programs jas2233@cornell.edu